Evidence map›Paper›PMID 25860291›Full record

ArticleBlood cancer journal2015

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.

M Dwojak, M Bobrowicz, J Bil, K Bojarczuk, B Pyrzynska, M Siernicka, A Malenda, E Lech-Maranda, W Tomczak, K Giannopoulos and 2 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

M Dwojak1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Postgraduate School of Molecular Medicine, Warsaw, Poland.
M Bobrowicz1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Postgraduate School of Molecular Medicine, Warsaw, Poland.
J Bil1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland.
K Bojarczuk1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Postgraduate School of Molecular Medicine, Warsaw, Poland.
B PyrzynskaDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.
M Siernicka1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Postgraduate School of Molecular Medicine, Warsaw, Poland.
A MalendaDepartment of Haematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland.
E Lech-Maranda1] Department of Haematology, Institute of Haematology and Transfusion Medicine, Warsaw, Poland [2] Department of Haematology and Transfusion Medicine, Centre of Postgraduate Medical Education, Warsaw, Poland.
W TomczakDepartment of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland.
K GiannopoulosDepartment of Experimental Haematooncology, Medical University of Lublin, Lublin, Poland.
J Golab1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Institute of Physical Chemistry, Polish Academy of Sciences, Department 3, Warsaw, Poland.
M WiniarskaDepartment of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedComplement System ProteinsGene Expression Regulation, LeukemicHumansLeukemia, Lymphocytic, Chronic, B-CellNiacinamidePhenylurea CompoundsRituximabSorafenibAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedComplement System ProteinsNiacinamideofatumumabPhenylurea CompoundsRituximabSorafenib

Identifiers

PMID25860291
PMCPMC4450327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.